Media - Journal & Press Releases
Cambridgeshire, UK, 25th June, 2009 – Quotient Bioresearch Limited (“Quotient”), a leading provider of drug development services, announces that it has reached an agreement to acquire Amersham Radiolabelling Services (“Amersham Radiolabelling Services”), the radiochemical custom synthesis operations of GE Healthcare. This represents Quotient’s seventh acquisition since its formation in early 2007.
ACQUISITION OF PHARMACEUTICAL PROFILES EXPANDS EARLY-PHASE DRUG DEVELOPMENT SERVICE OFFERING
Newmarket, United Kingdom, December 15, 2008
– Quotient Bioscience Group Limited ("Quotient"), a leading European provider of analytical and safety evaluation services and products for bioscience and sport, is pleased to announce that it has acquired Pharmaceutical Profiles Group Limited ("Pharmaceutical Profiles"). Pharmaceutical Profiles will become an important member of Quotient’s Drug Development Services Group - Quotient Bioresearch.
CAMBRIDGE UK, 04 December 2008. Quotient Bioresearch, a leading provider of early phase drug development and sports testing services, is pleased to announce the completion of a £4.5M, 19,000 ft2 laboratory build project at its Fordham site near Cambridge.
Alba Bioscience receives funding to secure 16 R&D jobs
Edinburgh-based Alba Bioscience announced a major investment today (Tuesday 16th September) to create and secure 16 high value research and development jobs and support the development of novel technologies in life science diagnostics.
Newmarket, United Kingdom, September 3, 2008
– Quotient Bioscience Group Limited ("Quotient" or "the Company"), a leading provider of analytical and safety evaluation services and products for bioscience and sport, today announced it has raised a significant minority investment of approximately £35 million from.....
Alba Bioscience has been granted clearance to supply blood typing reagents into
Canada, a significant move further strengthening the Company’s position on the
world stage.
Newmarket, United Kingdom, May 19, 2008
– Quotient BioResearch Limited, the leading provider of analytical and safety evaluation services and products for bioscience and sport, announces that following the recent acquisitions of HFL Limited, GR Micro Limited and BioDynamics Research Limited, it is consolidating its drug development services businesses under the name Quotient Bioresearch and renaming the parent company of the Group Quotient Bioscience Limited (“Quotient Bioscience”).
Further Expansion for Quotient BioResearch in drug development services acquisition of BioDynamics
Newmarket, United Kingdom, February 11, 2008 - Quotient BioResearch Limited ("Quotient BioResearch"), the leading European provider of analytical and safety evaluation services and products for bioscience and sport, is pleased to announce that it has acquired BioDynamics Research Limited ("BioDynamics").
Edinburgh based Alba Bioscience has successfully received FDA clearance to manufacture 15 monoclonal blood typing reagents for supply into the US market. These ready-to-use reagents are critical for safe blood transfusion and include some unique products not previously available in the US.
It's a fresh start for the Alba Bioscience Team
Newmarket and Edinburgh, United Kingdom, August 31, 2007 – Quotient BioResearch Limited is pleased to announce that, together with management, it has acquired 100% of the business and assets of Alba Bioscience from the Scottish National Blood Transfusion
Service.
This new product consist of a panel of twelve anti-D's, specially selected for use in the identification of partial RhD types.
|